AveXis Inc. (NASDAQ:AVXS) shares traded down 2.2% during mid-day trading on Friday . The stock traded as low as $38.31 and last traded at $39.33, with a volume of 219,937 shares traded. The stock had previously closed at $40.22.

Several research analysts recently issued reports on the company. Goldman Sachs Group Inc. raised their target price on AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research report on Friday, May 13th. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Wells Fargo & Co. assumed coverage on AveXis in a research report on Friday, July 15th. They set a “market perform” rating for the company. Jefferies Group lowered AveXis from a “buy” rating to a “hold” rating and raised their target price for the stock from $39.00 to $42.00 in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. Finally, Chardan Capital initiated coverage on AveXis in a research report on Monday, March 28th. They set a “buy” rating and a $60.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $43.80.

The firm has a 50 day moving average price of $40.13 and a 200 day moving average price of $30.73. The firm’s market capitalization is $906.94 million.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.89. Analysts predict that AveXis Inc. will post ($3.65) earnings per share for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.